Codagenix granted U.S. patent for codon-deoptimized RSV vaccine

  • The patent spans human codon-deoptimized RSV vaccine applicants in G and/or F and other RSV genes.
  • Recent accomplishment would enable the company to expand its intellectual property portfolio to include all modified RSV viruses.

Codagenix Inc. has recently made it to the headlines following the announcement of the company receiving a U.S patent for a vaccine fixated on human codon- deoptimized RSV (respiratory syncytial viruses) vaccine candidate.

It has been claimed that the issuance of Patent No. 10,695,414 would broaden the company’s intellectual property, encompassing human codon deoptimization of the RSV G and/or F proteins in a live-attenuated vaccine.

It would be crucial to note that the company is currently investigating its live attenuated CodaVax RSV vaccine in double blind, randomized, placebo-controlled Phase 1 clinical trial. Speculations have it that the top line data from the trial, which has been created to evaluate the tolerability, safety, and immunogenicity of CodaVaxTM-RSV in adults up to 75 years of age, would be rolled out by the second quarter of 2021.

As per credible reports, the patent on deoptimized RSV viruses is an addition to the patent family, spanning modulation of duplicative suitability of viruses by deoptimization of synonymous codons, which is exclusively licensed by Codagenix for human as well as animal health.

In a statement released by CEO of Codagenix, J. Robert Coleman quoted that the issuance of patent enables Codagenix to broaden its intellectual property portfolio to include all modified RSV viruses in which the G or/and F genes carry relatively more human deoptimized codons that the native virus.

He added that the company has always has codon-deoptimization as a part of its platform, and this patent grant further solidifies the IP position around its RSV vaccine range.

Codagenix’s RSV vaccine candidate has reportedly depicted brilliant safety and efficiency in non-human primate models, eliciting both cellular-based and antibody immune responses and protecting against RSV infections.

Source Credit: